C4 Therapeutics Inc expected to post a loss of 75 cents a share - Earnings Preview

C4 Therapeutics

01/05/2023 15:46

* C4 Therapeutics Inc  CCCC.OQ   CCCC.O  is expected to show
a
fall in quarterly revenue when it reports  results on May 3
(estimated). 
    * The Watertown Massachusetts-based  company is expected to
report
 a 28.6% decrease in revenue to $5.463 million from $7.65
million a year ago, according to the mean estimate from 7
analysts, based on Refinitiv data. 
    * ​Refinitiv's mean analyst estimate for C4 Therapeutics Inc
is
for a loss of 75 cents per share. 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 7 "strong buy" or "buy," 4
"hold" and 2 "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for C4
Therapeutics
Inc is $19​, above​ its last closing price of $3.02. ​​​

Previous quarterly performance (using preferred earnings measure
in US dollars). ​
 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2022  -0.73       -0.74      -0.77     Missed  -3.5
 Sep. 30 2022  -0.65       -0.67      -0.65     Beat    3
 Jun. 30 2022  -0.70       -0.69      -0.56     Beat    19.2​
 Mar. 31 2022  -0.56       -0.58      -0.65     Missed  -12.3
 ​​Dec.        -0.58       -0.58      -0.31     Beat    46.8
 31 2021                                                
 Sep. 30 2021  -0.57       -0.59      -0.51     Beat    13.8​
 Jun. 30 2021  -0.59       -0.59      -0.51     Beat    13.6
 Mar. 31 2021  -0.63       -0.63      -0.49     Beat    22.2
 This summary was machine generated May 1 at 14:46 GMT.  All
figures in US dollars  unless otherwise stated